Compare National Beverage Corp. (FIZZ) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Invesco Ltd. — how do they compare? National Beverage Corp. trades at $31.72 (market cap $2.89B), while Invesco Ltd. trades at $30.67 (market cap $13.43B). The key difference: Invesco Ltd. is far larger — about 4.6× National Beverage Corp.'s market cap, and Invesco Ltd. pays a 2.84% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | IVZ | |
|---|---|---|
Market Cap | $2.89B | $13.43B |
Sector | Consumer Cyclical | Financials |
52-Week High | $47.69 | $30.30 |
52-Week Low | $30.85 | $16.88 |
Enterprise Value | $2.60B | $23.68B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $31.47, up 1.78% today, but faces bearish technical signals with three consecutive earnings misses. The company maintains solid profitability with 15.56% net margins and 34.03% ROE, though revenue growth has stalled at $1.2B annually. Recent news highlights a $3.25 special dividend announcement but also concerns about LaCroix brand decline and muted growth prospects.
The outlook remains cautious with analyst sentiment skewed bearish (50% sell ratings) and technical indicators pointing downward. While the dividend provides shareholder return, fundamental challenges including competitive pressures and stagnant revenue create headwinds for meaningful price appreciation in the near term.
Invesco (IVZ) trades at $28.73, up 1.16% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $30.50. Recent earnings show a mixed track record, with a Q1 2026 miss after two prior beats, while the company maintains strong operating cash flow of $1.53B in 2025 despite a negative net income margin. A dividend of $0.22 per share was declared for H1 2026, payable in June.
The outlook is cautiously optimistic, supported by analyst upgrades and solid cash generation, but profitability challenges and competitive pressures in asset management pose risks. Upside potential exists if the company returns to sustained earnings growth and meets Q2 2026 EPS expectations of $0.66.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
